At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycledrug
Likely dose
ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cyclefrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label and Single Arm Study of ATG-010 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
In Brief
A Phase 2 clinical trial evaluating ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL). Completed, enrolled 60 participants across 18 sites.
Detailed Summary
This is an open-label, single arm, and registered study of ATG-010 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJun 2019
Enrollment StartApr 2020
Primary CompletionMay 2023
Study CompletionDec 2023
TodayJul 2026
First PostedJun 20, 2019
Enrollment StartApr 9, 2020
Primary CompletionMay 31, 2023
Study CompletionDec 1, 2023
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 7.0 years ago
Interventions
ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycledrug
Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010, orally, twice weekly, each 4 week (28-day) a cycle.